Peter Zdziarski/LinkedIn
Feb 18, 2026, 15:24
Peter Zdziarski: How Glanzmann Thrombasthenia Suddenly Became ‘Mainstream’?
Peter Zdziarski, Vice President and Marketing Director at Glanzmann’s Research Foundation, shared a post on LinkedIn։
”Recently posted in the incredible Glanzmann Thrombasthenia Support Group (with almost 1 thousand patients, family members, and doctors!)
Just thinking out loud:
Has anyone else noticed how GT suddenly became ‘mainstream’?
And just as fast, a wave of unknown experts showed up out of nowhere?
I wish I knew why, but the point is this:
You are the expert in your GT. Your lived experience matters more than any trending take.
I know our community has been cautious about attention in the past. But let’s take advantage of the spotlight and turn it into new treatments and possibly even gene therapy!”

Stay updated with Hemostasis Today.
-
Feb 18, 2026, 15:22Kanishk Kumar: Thalassemia Pipeline 2025 Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
-
Feb 18, 2026, 15:18Veronica Sanchez: First-Ever Interventional Recommendations for Pediatric Acute Ischemic Stroke
-
Feb 18, 2026, 15:07Flora Peyvandi: The Evidence Gap in Drug Safety During Pregnancy
-
Feb 18, 2026, 14:44Omolade Awodu Awodu։ Charting a Sustainable Path for Inherited Blood Disorders in Nigeria
-
Feb 18, 2026, 14:34Vincent Ten Cate: FXI(a) and Its Links With Cardiovascular Disease
-
Feb 18, 2026, 14:30Mohamed Sikkander Abdul Razak: A Single Stem Cell Generating 14 Million Tumor-Killing NK Cells
-
Feb 18, 2026, 13:26Jecko Thachil: Are There More Than Anticoagulants for Venous Thromboembolism Prophylaxis?
-
Feb 18, 2026, 12:41Davide Bartoli: The Hidden Cost of Informal Caregiving After Stroke
-
Feb 18, 2026, 12:34Amy Goundry: Which Are The Next Major Advances in Blood and Plasma-Driven Immune Regulation?